

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : G01N 33/569, 15/14, 21/64, C12Q 1/04		A1	(11) International Publication Number: WO 96/31777 (43) International Publication Date: 10 October 1996 (10.10.96)
(21) International Application Number: PCT/AU96/00192		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 3 April 1996 (03.04.96)		Published <i>With international search report.</i>	
(30) Priority Data: PN 2140 3 April 1995 (03.04.95) AU			
(71) Applicants (for all designated States except US): MACQUARIE RESEARCH LIMITED [AU/AU]; Macquarie University, NSW 2109 (AU). SYDNEY WATER CORPORATION LIMITED [AU/AU]; 51 Hermitage Road, West Ryde, NSW 2114 (AU).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): VESEY, Graham [GB/AU]; 10 Plunkett Street, Drummoyne, NSW 2047 (AU). VEAL, Duncan [GB/AU]; 70 Finlay Road, Turramurra, NSW 2074 (AU). WILLIAMS, Keith [AU/AU]; 23 Nandi Avenue, Frenchs Forest, NSW 2086 (AU).			
(74) Agent: F.B. RICE & CO.; 28A Montague Street, Balmain, NSW 2041 (AU).			

(54) Title: METHOD FOR DETECTING MICROORGANISMS

(57) Abstract

Methods for detecting microorganisms in a sample by binding detectable particles and fluorescent labelled ligands reactive to the microorganisms. The present invention also includes the use of multiple fluorochromes for the detection of microorganisms and is adaptable for use in flow cytometry.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Method for Detecting Microorganisms

Technical Field

The present invention relates to methods for detecting the presence of microorganisms in a sample using particles bearing a ligand reactive to the microorganisms and fluorescent labelled ligands. The methods are suitable for flow cytometric detection of microorganisms.

Background Art

Testing samples for the presence of microorganisms, in particular human pathogens, is an important part of monitoring samples including biological samples, foods, drinks, the environment and water supplies. In order to obtain immediate results, testing often involves the direct analysis of samples for specific microorganisms. This can be labour intensive and routine for the technician involved. In particular, there is an increasing need to monitor water supplies to ensure they meet strict standards for human consumption. This often involves the testing of large volumes of water in order to detect relevant numbers of microbial contaminants which is time consuming and expensive. Automated methods and apparatus are being developed to assist in the large scale testing of samples for microbial contamination. The methods presently in use are often insensitive and do not allow the identification of specific microorganisms present in the samples being tested.

Flow cytometric detection of specific microorganisms relies on labelling the target organism with highly specific probes attached to fluorochrome molecules. To enable accurate detection, two or more different fluorescent labels need to be attached to the target organism (Vesey *et al.* 1994A). The types of probes available for these techniques are monoclonal and polyclonal antibodies, lectins and oligonucleotides. The range of fluorochromes that can be coupled to these probes is limited. For example, many flow cytometers utilise a 488 nm laser to illuminate the sample, and accordingly, the choice of fluorochromes is limited to those which can be excited at 488 nm for those machines.

For a flow cytometer to distinguish one fluorochrome from another, the fluorochromes must emit at different wavelengths. There are only three types of fluorochromes presently available that excite at 488 nm and emit at wavelengths different enough to be distinguished by flow cytometry: green fluorochromes such as fluorescein isothiocyanate (FITC); red fluorochromes

such as phycoerythrin (PE) and tandem fluorochromes. Unfortunately, the tandem fluorochromes are often not bright enough to be used in many applications. Therefore, flow cytometry is often limited to the detection of two fluorochromes. In applications such as the detection of specific 5 microorganisms in a range of sample types, this poses a problem if there are only a small number of sites available for recognition on the microorganism. The level of sensitivity that can be achieved with two fluorochromes is often not good enough for these applications.

10 The present inventors have developed methods of detecting microorganisms in a fluid sample utilising particles and fluorescent labelled ligands reactive to microorganisms.

Disclosure of the Invention

15 Accordingly, the present invention consists in a method of detecting the presence of microorganisms of a predetermined type in a sample containing the microorganisms, the method comprising the steps of:

20 (a) treating the sample with at least one detectable particle, each particle bearing a ligand reactive to the microorganisms of the predetermined type, the sample being treated for a period of time sufficient to allow the microorganisms of the predetermined type in the sample to bind to the particle via the ligand;

25 (b) further treating the sample with at least one ligand labelled with a fluorescent marker, the ligand being reactive to the microorganisms of the predetermined type, the sample being treated for a period of time sufficient to allow the at least one ligand to bind to the microorganisms of the predetermined type; and

30 (c) analysing the sample so as to detect the presence of a particle associated with one or more of the fluorescent markers, the ligands being so selected that such an association is indicative of the presence of microorganisms of the predetermined type in the sample.

35 In a preferred embodiment of the present invention the particle is a fluorescent particle and more preferably a fluorescent latex bead. The beads preferably have a nominal diameter from 10 nanometres to 0.1 millimetres. The beads are preferably detectable by virtue of being fluorescently labelled. More than one type of particle can be used with each type bearing a ligand reactive to the same or different type of microorganism to be detected. It

would, however, be within the scope of the invention to detect the bead by magnetism, by charge, by density difference or in any other suitable manner.

In a further preferred embodiment of the present invention the ligand is selected from the group consisting of antibody, lectin and 5 oligonucleotide. Preferably, at least one of the ligands is a monoclonal antibody. When the particle is a fluorescent particle, the fluorescent markers attached to the at least one ligand have different fluorescent spectra to that of the fluorescent particle.

In a still further preferred embodiment, the analysing of the treated 10 sample is by flow cytometry, the microorganisms being detected by the presence of fluorescence of the labelled ligand or in combination with the size of the particle, or more preferably, fluorescence of both the marker and the particle. With regard to the detection of the size of the particle, this 15 includes either detecting the known size of the particle or detecting or measuring for an increased size caused by the binding of microorganisms to the particle.

In a still further preferred embodiment of the present invention, the 20 particle is labelled with several ligands reactive to the same or different microorganisms. Furthermore, several different particles can also be used having the same or different ligands bound thereto. For example, in step (b) several different ligands reactive to the same or different microorganisms but provided with different fluorescent markers are utilised to allow the possible detection of more than one type of microorganism bound to the particle.

The method according to the present invention preferably uses one 25 or more fluorescent markers that are excited at 488 nm and emit at wavelengths ranging from green to infra-red. It will be appreciated by one skilled in the art that fluorescent markers that are excited at other wavelengths are also suitable for the present invention.

The present invention is suitable for detecting multiple forms of the 30 same species of microorganism or detecting several different microorganisms from the same sample. The microorganisms bound to the particle may be further treated or analysed after being detected by the method of the present invention.

The number of particles used in the present methods will depend on 35 the type of particle, the type of sample being tested, and the number and type of microorganisms in the sample. It will be appreciated that the

microorganism must come in contact with a particle to allow binding. Therefore, the number of particles should be in excess to the number microorganisms in a given sample to ensure detection of the microorganisms of interest. In order to assist in this regard usually at least 10^3 particles per ml, preferably between 10^4 to 10^7 particles per ml are used. When a sample has a lot of particulate material present then usually a higher number of detectable particles is used in order to increase the possibility that the microorganisms present in the sample will come into contact with the particles and bind. The present invention has the advantage that the number of microorganisms in a sample can also be estimated by adding a known number of detectable particles to the sample and counting all of those particles to determine the number that have bound microorganisms. Furthermore, by adding a known number of particles to the sample it is also possible to confirm that the sample was correctly analysed by enumerating the number of particles detected.

In order that the nature of the present invention may be more clearly understood, preferred forms thereof will be described with reference to the following examples and drawings.

Brief Description of the Drawings

Figure 1 shows flow cytometry scatter plots representing *Cryptosporidium* oocysts captured onto fluorescent beads and then bound with a FITC-conjugated *Cryptosporidium*-specific antibody; and

Figure 2 shows flow cytometry scatter plots representing *Adenovirus* captured onto fluorescent beads and then bound with FITC-conjugated *Adenovirus*-specific antibody.

Modes for Carrying Out the Invention

MATERIALS AND METHODS

Coating beads with antibody

TransFluorSphere 488/685 latex beads were coated as recommended by Molecular Probes (Eugene, USA) with antibody specific to the microorganism of interest.

Antibody (2 mg) specific to either *Cryptosporidium* (Biox, Sydney), *Adenovirus* (Silenus, Melbourne) or *Salmonella typhimurium* (Wellcome Diagnostics) was dissolved in 1 ml of 50 mM Tris buffer (pH 8.4) and then dialysed overnight at 4°C against 50 mM MES buffer (pH 6.0). The antibody was then mixed with 5 ml of 0.2% (w/v) 1 μ m latex beads (TransFluorSphere

488/685, Molecular Probes, Eugene USA) and incubated at room temperature for 15 min before the addition of 1-ethyl-3(3-dimethylaminopropyl)-carbodiimide (40 mg). The pH was then adjusted to 6.5 by the addition of 0.1 M NaOH. After incubation at room temperature for 2 hours, glycine was 5 added to give a final concentration of 100 mM and the sample incubated for a further 30 min. The beads were then pelleted by centrifuging (13000g for 2 min) and the pellet resuspended in 1% (w/v) bovine serum albumin (BSA) in phosphate buffered saline (pH 7.2). The washing procedure was repeated three times before the addition of 0.1%(w/v) sodium azide. The final sample 10 volume was 4 ml. Beads were sonicated for 30 min prior to use.

Using beads to label *Cryptosporidium* oocysts in water samples

River water samples were concentrated by calcium flocculation (Vesey *et al.* 1993). Portions (1 ml) of the concentrate were seeded with approximately 1,000 oocysts. BSA was added to a concentration of 1% (w/v) 15 prior to the addition of 20 μ l of the crypto-antibody-coated bead suspension. Samples were then incubated at room temperature on a rotary mixer for 30 min.

Oocysts were then labelled with a second fluorochrome. Monoclonal antibody, specific to *Cryptosporidium* oocysts walls, conjugated with fluorescein isothiocyanate (Cellabs Pty Ltd, Sydney, Australia) was added 20 (0.5 ml) and the samples incubated at 37°C for 20 min.

Using beads to label *Salmonella*

Salmonella typhimurium was cultured on MacConkey agar, fixed in 5% (v/v) formalin for 15 min and washed by centrifuging (13000g for 10 min) 25 and resuspending in PBS. An aliquot (100 μ l) containing approximately 1 \times 10⁶ cells was mixed with 20 μ l of bead suspension (coated with *Salmonella* antibody) and then incubated on a rotary shaker for 30 min a room temperature. *Salmonella* cells attached to beads were labelled with a second fluorochrome by incubating with rabbit anti-*Salmonella* antibody (Wellcome 30 Diagnostics), washing by centrifuging at 13000g for 30 seconds, resuspending in a goat anti-rabbit 7-amino-4-methylcoumarin-3-acetic acid (AMCA) (Dako, Glustop, Denmark) conjugated antibody and incubating for 10 min at 37°C. Samples were examined using epifluorescence microscopy. Samples were analysed immediately.

Using beads to label *Adenovirus*

Adenovirus was cultured in human epithelial cells, harvested by freeze thawing the cells and then purified from cell debris by centrifuging (13000g for 2 min) and retaining the supernatant. The supernatant was then 5 mixed with 20 µl of the bead suspension (coated with *Adenovirus* antibody) and then incubated on a rotary shaker for 30 min at room temperature. *Adenovirus* attached to beads were labelled with a second fluorochrome by incubating with the same *Adenovirus* antibody conjugated with FITC for 20 min at 37°C.

10 Sample analysis

Samples were analysed using a Becton Dickinson Facscan flow cytometer. The discriminator was set on red fluorescence (FL4) at a level slightly less than the fluorescence of the beads. A region (R1) on a scatter plot of green fluorescence (FL1) verses side scatter (graph 1) was defined 15 which enclosed the FITC-labelled oocysts. This region was then used to gate a scatter plot of red fluorescence verses side scatter (graph 2). A region was defined on this second scatter plot which enclosed oocysts attached to beads. The same process was also used for analysis of *Adenovirus* (Fig. 2).

20 Colour compensation was performed to separate the fluorescence of the beads from the fluorescence of the labelled organism. Red fluorescence was progressively subtracted from green fluorescence until a second population appeared on the green fluorescence verses side scatter graph.

RESULTS

Cryptosporidium

25 Analysis of the *Cryptosporidium* sample by flow cytometry resulted in a distinct population on graph 1 (Figure 1). This population represents all beads and was enclosed within a region (R1). Gating a graph of side scatter verses FITC on the region R1 produced the scatter graph 2 (Figure 1). Two 30 populations are observed on graph 2, a large population with a low green signal (spill over from high level of red fluorescence from the beads) which represent the beads and a smaller population with a high FITC signal which represent beads attached to FITC-labelled oocysts.

Adenovirus

35 Viruses could be detected on the flow cytometer when using the gating and colour compensation procedures that were used for *Cryptosporidium*. A scatter plot representing a large population of beads

with low FITC fluorescence and a small population of beads with high FITC fluorescence (Figure 2) was observed. This second population represents viruses attached to beads and labelled with FITC. The negative control did not contain any beads with a high FITC signal.

5 **Salmonella**

Examination of the beads using epifluorescence microscopy revealed red fluorescing beads attached to blue (AMCA) fluorescing *Salmonella* cells.

10 The detection of specific or predetermined microorganisms with flow cytometry has the potential to replace existing methodologies for the detection of microorganisms in samples ranging from clinical fluids, water, food and beverages. One way to enable simple and rapid flow cytometric detection of low numbers of microorganisms is to use at least two different coloured fluorochromes for attached to the microorganisms. These fluorochromes are attached to the microorganism via highly specified 15 ligands such as antibodies. This has been achieved previously by conjugating different coloured fluorochromes directly to antibodies (Vesey *et al.* 1994A).

20 The present inventors have shown that microorganisms can be detected by flow cytometer by attaching fluorescent beads to the microorganisms. The population representing oocysts attached to beads displayed in graph 2 (Figure 1) is an identifiable population totally clear from any unassociated coloured bead or interfering noise. The population representing viruses attached to beads in Fig. 2 is also an identifiable population.

25 The technique of using a fluorescent particle to tag a specific or predetermined microorganism with a fluorescent label has several advantages over using only a fluorochrome-conjugated antibody. Firstly, only a single bead needs to be attached to the microorganism to achieve detectable fluorescence. To achieve the same level detection using only a 30 fluorochrome conjugated antibody requires thousands of antibodies to be attached to the microorganism. These thousands of antibodies cover and mask available antigen sites. If only a single type of antigen is available on the surface of a microorganism, then it is not always possible to label the surface of the organism with a second antibody. The present inventors have 35 found that only one antigen is presented by *Cryptosporidium* and therefore this organism is difficult to detect by previous methods.

If the microorganism is labelled with an antibody coated fluorescent bead then there are many antigen sites still available on the surface of the organism for attaching an antibody conjugated to a fluorochrome. This technique enables two colour fluorescence labelling of a microorganism with 5 a single antibody as shown by the present inventors.

A further advantage of the fluorescent bead labelling technique is that it enables the use of new fluorescence emission wavelengths. Until recently the number of different colours that can be detected by a single laser flow cytometer has been limited to two. These are a green 10 fluorochrome such as FITC and a red fluorochrome such as PE. A third colour is now possible using tandem fluorochromes such as PE/Texas red where the PE pumps the Texas red. These tandem fluorochromes however are not bright enough for many applications. When attempting to detect microorganisms the fluorescence signals need to be very bright. The 15 fluorescent beads enable the use of a third and even a fourth very bright fluorescent signal. This is because beads with a range of different fluorescent emissions are available. Beads with emissions as far into the infra-red as 720 nm are available.

Examples of fluorescent beads and their production that are suitable 20 for use in the present invention can be found in US patent 5326692.

The use of fluorescent beads as a label improves flow cytometric detection. This is because the beads can be used as the size or fluorescence discriminator. The cytometer can be set so that it ignores all other particles except for the beads. This overcomes coincidence problems due to the 25 sample containing more particles than the cytometer can examine. It also means that a known number of particles need to be examined for all samples.

The bead technology is highly applicable to the detection of bacteria. It enables multiple bright fluorescence signals to be achieved on the surface 30 of a range of bacteria. The production of antibodies to large groups of bacteria (eg all gram negative bacteria) and then coating beads with these antibodies will allow the use of a single reagent for a range of microorganisms or their sub-types.

The application where this bead technology will have the most 35 benefits will be the flow cytometric detection of very small particles such as viruses. Coating beads with virus specific antibodies and reacting with

samples captures viruses onto the beads. The virus is then labelled with a second fluorochrome enabling detection. This is the first, simple virus detection procedure that can be performed within minutes.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

10 References

Vesey, G., Narai, J., Ashbolt, N., Williams, K.L. and Veal, D. 1994A. Detection of specific microorganisms in environmental samples using flow cytometry, p.489-522. *In Methods in Cell Biology-Flow Cytometry Second Edition*. Academic Press Inc., New York.

15 Vesey, G., Hutton, P.E., Champion, A.C., Ashbolt, N.J., Williams, K.L., Warton, A. and Veal, D.A. 1994B. Application of flow cytometric methods for the routine detection of *Cryptosporidium* and *Giardia* in water. *Cytometry*, **16**: 1-6.

20 Vesey, G., Slade, J.S., Byrne, M., Shepherd, K., and Fricker, C.R., 1993. A new method for the concentration of *Cryptosporidium* oocysts from water. *J. Appl. Bact.* **75**:82-86.

Claims

1. A method of detecting the presence of microorganisms of a predetermined type in a sample containing the microorganisms, the method comprising the steps of:
 - 5 (a) treating the sample with at least one detectable particle, each particle bearing a ligand reactive to the microorganisms of the predetermined type, the sample being treated for a period of time sufficient to allow the microorganisms of the predetermined type in the sample to bind to the particle via the ligand;
 - 10 (b) further treating the sample with at least one ligand labelled with a fluorescent marker, the ligand being reactive to the microorganisms of the predetermined type, the sample being treated for a period of time sufficient to allow the at least one ligand to bind to the microorganisms of the predetermined type; and
 - 15 (c) analysing the sample so as to detect the presence of a particle associated with one or more of the fluorescent markers, the ligands being so selected that such an association is indicative of the presence of microorganisms of the predetermined type in the sample.
2. The method according to claim 1 wherein the particle is a fluorescent particle.
3. The method according to claim 2 wherein the fluorescent particle is a fluorescent latex bead.
4. The method according to claim 3 wherein the bead has a nominal diameter from 10 nanometres to 0.1 millimetres.
- 25 5. The method according to any one of claims 1 to 4 wherein the sample is treated with at least 10^3 detectable particles per millilitre sample.
6. The method according to claim 5 wherein the sample is treated with between 10^4 and 10^7 detectable particles per millilitre sample.
7. The method according to any one of claims 1 to 6 wherein the
- 30 microorganisms are selected from the group consisting of bacteria, fungi and viruses.
8. The method according to any one of claims 1 to 7 wherein the ligands are selected from the group consisting of antibody, lectin and oligonucleotide.
- 35 9. The method according to claim 8 wherein at least one of the ligands is a monoclonal antibody.

10. The method according to any one of claims 1 to 9 wherein the one or more fluorescent markers are excited at 488 nm and emit at wavelengths ranging from green to infra-red.

11. The method according to any one of claims 2 to 10 wherein the 5 fluorescent marker of the at least one labelled ligand has a different fluorescence spectrum to that of the fluorescent particle.

12. The method according to any one of claims 1 to 11 wherein the analysing of the treated sample is by flow cytometry.

13. The method according to claim 12 wherein the microorganisms are 10 detected by the presence of fluorescence of the labelled ligand, by fluorescence of the labelled ligand in combination with the size of the particle, or by fluorescence of both the ligand and the particle.

14. The method according to any one of claims 1 to 13 wherein the 15 particle bears several ligands reactive to the same or different microorganisms.

15. The method according to any one of claims 1 to 14 wherein step (b) includes several different ligands, each different ligand being labelled with a different fluorescent marker.

16. The method according to any one of claims 1 to 14 wherein the 20 detectable particle bears several different ligands, each ligand reactive to a different predetermined type of microorganism. step (b) includes several different ligands, each different ligand being labelled with a different fluorescent marker and being reactive to a different type of microorganism so as to allow detection of more than one type of microorganism in the sample 25 by analysing for the presence of more than one different fluorescent-labelled ligand associated with the particle.

17. The method according to any one of claims 1 to 16 wherein the 30 number of microorganisms of a predetermined type in the sample is estimated by adding to the sample a known number of detectable particles and analysing all the particles in the sample for association with one or more of the fluorescent markers and estimating the number of microorganisms in the sample from the number of detectable particles associated with the fluorescent markers.

1/2




Fig. 1

2/2




Fig. 2

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 96/00192

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl⁶ G01N 33/569, 15/14, 21/64; C12Q 1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
G01N 33/53:, 33/54:, 33/55:, 33/56:, 33/57:, 15 and 21Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
AU as aboveElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Chemical abstracts
Derwent (WPAT)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86/06493 A (LAB-SYSTEMS OY) 6 November 1986 See entire specification, in particular page 1 lines 30-35, figure 1, page 3 lines 2-25	1, 7-10
X	US 5290707 A (S.J. Wood) 1 March 1994. See entire specification, in particular see claim 1, abstract, column 6 lines 19-48, column 7 lines 16-44	1,7-9,12-14,17
X	US 4421860 A (V.B. Elings & D.F. Nicoli) 20 December 1983, see entire specification, in particular figure 6	1,7-10,13-14

 Further documents are listed in the continuation of Box C See patent family annex


* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
5 July 1996Date of mailing of the international search report
15 JUL 1996Name and mailing address of the ISA/AU
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION
PO BOX 200
WODEN ACT 2606
AUSTRALIA Facsimile No.: (06) 285 3929

Authorized officer

NORMAN BLOM

Telephone No.: (06) 283 2238



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 96/00192

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86/04684 A (LAB-Systems OY) 14 August 1986, see entire document, in particular page 1 line 32 - page 2 line 1, figures 5-8	1,7-10,13-14
X	US 4665020 A (G.C. Saunders) 12 May 1987, see entire document, in particular claim 8	1,9-10,12-14,17
X	EP 536593 A (Cannon Kabushiki Kaisha) 14 April 1993, see entire document, in particular page 4 column 4 line 57 to page 5 column 5 line 3.	1-13, 17
X	EP 63852 A (Syva Company) see entire document	1,7-10, 13-14
X	EP 216191 A (Abbott Laboratories) 1 April 1987 entire document, in particular: example 1	1,7-10, 13-14
X	GB 2095831 A (Mochida Seiyaku K.K.) 6 October 1982, see page 4 lines 25-46, claim 1	1,7-10,13-14
X	WO 84/04169 A (Quidel) 25 October 1984, see entire document, in particular page 4 lines 34-36, page 6 line 24, page 7 lines 2 and 25-28	1,7-9,13
X	EP 201211 A (Whittaker Corporation) 12 November 1986, see in particular page 1 line 33, page 2 lines 27-28, page 9 lines 8-24, page 10 lines 10-25	1,7-9,13-14
Y	EP 149565 A (Amersham International PLC) 24 July 1985. Entire specification, in particular page 1 line 6, page 3 lines 1-9, page 5 lines 19-26, page 8 line 10 and claim 1	1,8-9,13-14
X	EP 124050 A (Pandex Laboratories Inc.) 7 November 1984, see entire specification, in particular page 3 lines 5-18, 26, page 4 lines 1-5, page 6 lines 1-13, claims	1,7-10,13-14
X	EP 595641 A (Becton Dickinson & Co) 4 May 1994, see entire document	1,7-10,13-14
Y	US 4780423 A (B.I. Bluestein et al.) 25 October 1988, see entire document, in particular column 6 lines 1-4, claim 1	
Y	EP 296136 A (Wallac OY) 21 December 1988 see entire specification	1-15,17
A	DE 3806558 A (Hitachi Ltd.) 15 September 1988 see entire document, in particular figures 5 and 6.	1
X	Derwent abstract accession no 94-194207/24, class S03, JP,A, 06-130063 (Sanyo chem Ind. Ltd) 13 May 1994. See entire abstract	1,7-10,13-14
X	Derwent abstract accession no. 94-002493/01, class B04 D16, JP,A, 05-312811 (Cannon K.K.) 26 November 1993 see entire abstract	1
X	Derwent abstract accession no. 86-200845/31, class S03, JP,A, 61-132869 (Olympus optical K.K.) 20 June 1986 see entire abstract	1,8-10,12-14 and 17

INTERNATIONAL SEARCH REPORT
International Application No.
PCT/AU 96/00192

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Derwent abstract accession no. 94-077445/10, class S03, JP,A, 06-027112 (Nitto Denko Corp) 4 February 1994 see entire abstract	1,7-10,12-15
X	Derwent abstract accession No. 93-173192/21, class S03, JP,A, 05-107249 (Toyobo K.K.) 27 April 1993 see entire abstract	1-4,7-14
Y	Derwent abstract accession No. 93-380051/48, class S03, JP,A, 05-281230 (Toyobo K.K.) 29 October 1993 see entire abstract	1,7-10,13
Y	Methods in cell biology, volume 42, (1994), pages 489-521 "Detection of specific Microorganisms in Environmental Samples using flow cytometry", G. Vesey et al., see in particular page 497, 514 and 518-519.	1,7-10,13-14
Y	Journal of immunological methods, <u>178</u> (1), (1995), pages 141-151 "Dual analyte assay based on particle types of different size measured by flow cytometry" J. Frengen et al. See entire document	1,4-9,12-13
A	Analytical proceedings <u>30</u> (6), (1993) pages 253-255, "Selective particle counting by means of Affinity ligands linked to microscopically visible labels" D. Craston et al. See entire document	1
X	Derwent abstract accession No. 88-152784/22. class J04, JP,A, 63-095357 (Showa Denko KK.) 26 April 1988. See entire abstract	1,7-10,13-14
X	Derwent abstract accession No. 90-221834/29, class S03, JP,A, 02-151766 (Nippon teleg. and telephone) 11 June 1990 See entire abstract	1,7-10,13-14
X	Derwent abstract accession No. 90-278559/37, class S03, JP,A, 02-195257 (Aloca Co. Ltd) 1 August 1990 see entire abstract	1,8-10,13-15
Y	Derwent abstract accession No. 94-222930/27, class S03, JP,A, 06-160387 (Mitsubishi Kasei Corp) 7 June 1994 see entire abstract	1,13
X	Derwent abstract accession No. 94-153813/19, class S03, JP,A, 06-094716 (Kanebo Ltd) 8 April 1994 see entire abstract	1,7,13
A	FR, A, 2638849 (Chemunex) 11 May 1990 see entire document	1

INTERNATIONAL SEARCH REPORT**Information on patent family members**

International Application No.

PCT/AU 96/00192

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
WO	86/06493	EP,A	220255	FI,A	851702	FI,A	865002
US,A	4421860	US,A	4407964				
WO	86/04684	EP,A	214167	FI,A	850481	FI,A	864044
EP,A	536593	JP,A	5093726				
EP,A	216191	CA,A	1268419	JP,A	62075266	US,A	4748110
GB,A	2095831	CH,A,	658131	DE,A	3205849	FR,A	2500166
		IT,A	8247814	IT,A	1147626	JP,A	57136165
		NL,A	8200631	SE,A	8200978		
WO	84/04169	AU,A	23466/84	EP,A	141818		
EP,A	201211	JP,A	61286755				
EP,A	149565	GB,A	8401368	JP,A	60159651	US,A	4745077
EP,A	124050	JP,A	59208463	US,A	4652533		
EP,A	296136	JP,A	1035268	SE,A	8702511	US,A	5028545
DE,A	3806558	JP,A	63214668				
EP,A	595641	AU,A	48709/93	CA,A	2109461	CN,A	1088310
		FI,A	934804	JP,A	6281651	NO,A	933919
		US,A	5342790				
EP,A	63852	AU,A	78892/81	CA,A	1174166	ES,A	509142
		IL,A	64574	JP,A	57179730	US,A	4650770
END OF ANNEX							